John Houston, Arvinas CEO

Arv­inas’ prostate can­cer treat­ment shows hints of sig­nal — but how many pa­tients will it work for?

Arv­inas re­leased in­ter­im re­sults Thurs­day morn­ing on one of its pro­tein de­grad­er drugs for prostate can­cer ahead of a fire­side chat at the Jef­feries in­vestor con­fer­ence.

The droplet of ef­fi­ca­cy da­ta sug­gest Arv­inas’ drug can help re­duce lev­els of a bio­mark­er el­e­vat­ed in prostate can­cer, and po­ten­tial­ly shrink tu­mors, but the drug was de­signed for a spe­cif­ic (and small) sub­set of pa­tients.

In four pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer (mCR­PC) eval­u­at­ed for whether their tu­mors re­spond­ed to Arv­inas’ treat­ment ARV-766, which is an an­dro­gen re­cep­tor de­grad­er, one had a con­firmed par­tial re­sponse and one had an un­con­firmed par­tial re­sponse. And in 12 pa­tients eval­u­at­ed for PSA lev­els, a com­mon mark­er used to as­sess prostate can­cer, five saw their PSA lev­els drop by 50%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.